Sixth Floor<br>Shirokanedai 3-16-13, Usuibiru
5 articles with Ribomic, Inc.
RIBOMIC, Inc. , a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (TOKYO:4591), today announced that the first subject in cohort 1 was administered with RBM-007 subcutaneously in Phase 1 clinical trial in Japan. This represen
RIBOMIC Inc. , today announced that RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Sout
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.
RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration
RBM-007 was well-tolerated with no dose-limiting toxicities, no systemic or ocular serious adverse events.
Archemix Corporation Expands Collaboration with Ribomic, Inc. for Rights to Develop Aptamer Therapeutics for Multiple Drug Targets; Archemix Will Receive an Upfront Payment of $6 Million with a Total Potential Payment of $200M